Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer
In advanced NSCLC after chemotherapy progression, plasma-detected SGVs are common, and associated with inferior OS. Plasma SGV status should be considered as a stratification factor in future trials.
Authors
- Janene Dalrymple (ORCID: https://orcid.org/0009-0005-9794-3949)
- Danielle Klingberg
- Frank Lin (ORCID: https://orcid.org/0000-0001-9250-6874)
- Sarah J. Lord (ORCID: https://orcid.org/0000-0003-2763-5949)
- Chee Khoon Lee (ORCID: https://orcid.org/0000-0003-2955-9820)
- Wendy A. Cooper (ORCID: https://orcid.org/0000-0001-5418-4229)
- Robert John Simes (ORCID: https://orcid.org/0000-0002-3740-7563)
- Milita Zaheed (ORCID: https://orcid.org/0000-0002-2495-0209)
- Deborah Di-Xin Zhou (ORCID: https://orcid.org/0000-0001-5918-4439)
- Thomas John (ORCID: https://orcid.org/0000-0003-3399-5342)
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Prince of Wales Hospital (AU)
- St George Hospital (AU)
- National Health and Medical Research Council (AU)
- Western Sydney University (AU)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1200/po-24-00673
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00